GCAP2 Activators
GCAP2 activators are compounds that, rather than directly binding to and activating GCAP2, induce a cellular environment that facilitates GCAP2 activation of RetGCs. These compounds commonly exert their effects by altering intracellular calcium levels or manipulating the balance of cyclic nucleotides, particularly cGMP, within the cell.
Calcium channel blockers such as nitrendipine, isradipine, nifedipine, and amlodipine reduce intracellular Ca2+ levels. This decrease in Ca2+ is a signal for GCAP2 to assume its active conformation and stimulate RetGCs, which leads to an increase in cGMP synthesis essential for the visual cycle. On the other hand, phosphodiesterase inhibitors like sildenafil, vardenafil, tadalafil, and others indirectly maintain high cGMP levels by preventing its breakdown. Elevated cGMP levels mimic the conditions under which GCAP2 activates RetGCs.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nitrendipine | 39562-70-4 | sc-201466 sc-201466A sc-201466B | 50 mg 100 mg 500 mg | $109.00 $160.00 $458.00 | 6 | |
Blocks L-type calcium channels, decreasing intracellular calcium levels. Reduced calcium allows GCAP2 to activate RetGCs. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Inhibits L-type calcium channels leading to decreased intracellular Ca2+, which in turn enables GCAP2 to activate RetGCs due to its increased affinity for RetGCs in a low Ca2+ environment. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
By blocking L-type calcium channels, this compound reduces intracellular calcium, which could induce the activation state of GCAP2 that stimulates RetGCs. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Another calcium channel blocker that by lowering intracellular calcium concentrations can indirectly allow GCAP2 to become more active in its support of RetGCs. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Similar to sildenafil, this compound increases cGMP levels by inhibiting PDE5, which may help maintain GCAP2 in a state that can activate RetGCs. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Inhibits PDE5 leading to increased cGMP concentrations, which can indirectly ensure GCAP2 remains in an active state, capable of activating RetGCs. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Directly stimulates adenylate cyclase, leading to increased cAMP levels. Although cAMP is different from cGMP, it can indirectly influence the cGMP pathway and thereby GCAP2's activation of RetGCs. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases that increases levels of cAMP and cGMP, potentially keeping GCAP2 in an active state and able to facilitate the activation of RetGCs. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Inhibits PDE3, which leads to increased cAMP and may also affect cGMP levels, potentially influencing the activation state of GCAP2 and its ability to stimulate RetGCs. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Inhibits various phosphodiesterases and increases cGMP levels. Elevated cGMP can indirectly maintain GCAP2 in an active conformation, enabling it to activate RetGCs more effectively. | ||||||